Company OverviewCompany Overview

© Copyright 2010 CollPlant1October 2010

Forward Looking StatementsThe following overview contains forward-looking statements that include, but are not limited to,projections about our business and our future revenues, expenses and profitability. Forward-lookingstatements involve known and unknown risks, uncertainties and other factors which may cause the

t l t lt f i t hi t f th C t b t i llactual events, results, performance, circumstances or achievements of the Company to be materiallydifferent from those expressed or implied by such forward-looking statements due to factors thatinclude, but are not limited to: (1) our ability to develop and bring to market new products (2) ourability to successfully complete any necessary or required pre-clinical and/or clinical studies with ourproducts, if so requires (3) our ability to receive regulatory clearance or approval to market ourproducts, if so requires (3) our ability to receive regulatory clearance or approval to market ourproducts, if so requires, including due to changes in regulatory environment (4) our success inimplementing our sales, marketing and manufacturing plans (5) the level of adoption of our productsby medical practitioners (6) the emergence of other products that may make our products obsolete (7)protection and validity of patents and other intellectual property rights and (8) the effect of competitionb th i d/ t h l iby other companies and/or technologies.You are cautioned not to place undue reliance on these forward-looking statements, which speak onlyas of the date of this overview.In order to have a comprehensive understanding and information over the Company, including therisks its activity is subject to, you must review the Company's Immediate and Periodical reports withthe Israeli Security Authority and the Tel Aviv Stock Exchange.The Company undertakes no obligation to update any forward-looking statements, to report events orto report the occurrence of unanticipated events that may lead to the actual events, results,

f i t hi t f th C b i diff t th i d bperformance, circumstances or achievements of the Company being different than as envisaged bysuch forward looking statements.This overview by no means establishes an offer to purchase or sale the Company's securities nor aninvitation to receive such offer and is intended for informative purposes only."

2

CollPlant’s ProfileProduction of recombinant type I human collagen intransgenic tobacco plants

Platformtransgenic tobacco plants

Development and manufacturing of raw collagen andcollagen based pharmaceutical productsFocus collagen-based pharmaceutical products

Substantial pipeline including soft and hard tissuerepair products for orthopedic applications and forPipeline repair products for orthopedic applications and foradvanced wound care products

HQ & labs in the Weizmann Science Park Ness

Pipeline

HQ & labs in the Weizmann Science Park, NessZiona, Israel. Tobacco growing and processingfacilities in several locations in Israel and the US

Locations

Founded in 2004 based on the Hebrew University inJerusalem technologyBackground

3

Collagen is the Most Abundant Protein in Human BodyProtein in Human Body• Collagen is the principal protein of the skin, tendons, cartilage, bone and

other connective tissue. “It is the glue that holds the body together”.• More than 1,000 medical devices in the market are based on collagen

4Source: Tissue Engineering Options for Ligament Healing, Joseph W. Freeman

A Diagram of Tendon/Ligament Organization

Co-Expression of 5 Genes by Transformation and Cross-Breeding, Generating a Stable Plant Line

5

Why Tobacco?y

G P d i fGreen Production - the system is a safe alternative to animal/mammalian expression systems (FDA register January 2007)Tobacco is easily manipulated using known biotechnology practicesTobacco is easily manipulated using known biotechnology practicesTobacco produces large biomass, 4-6 weeks to mature plantTobacco is not in the food/feed chain (in-line with FDA regulations)

6

CollageTM

From Plant to Product

7

Farming of CollagenProducing Tobacco Plants in IsraelProducing Tobacco Plants in Israel

C t t f t b i• Contract farmers grow tobacco in greenhouses

• Scalability – fast with no capitalScalability fast with no capital requirements

• High return for the farmer, competitive f Ccost for CollPlant

• Advanced agriculture in Israel contributing to increasing yieldscontributing to increasing yields

8

Uses of Collagen-Based Products

• Bone, cartilage & meniscus repairW d • Wound care

• Surgical meshes• Vascular grafts• Corneal shields• Hemostasis• Surgical sutures• Drug delivery solutions

Industry is focused on supply of new, safer biomaterials*  * 2008 collagen & HA biomaterials – global strategic business report, March 2008 by Global Industry Analyst Inc.

9

Vergenix™ Accelerates Human Cells ProliferationProliferation

0 2

0.3

0.4Human keratinocytes *

0.0

0.1

0.2

(AU

)

Collage membrane induces increased human primary dermal cell proliferation

0 4

0.6

0.8

1Human Endothelial Cells

ifera

tion

*

1

0

0.2

0.4

Human Dermal fibroblastsCel

l pro

l

*

0.4

0.6

0.8 Collage membrane Control 72 h Cell proliferation

Control PuracolFibracol

0

0.2

Cells were seeded in low density and allowed to proliferate on 6 mm scaffold discs for 72 h. WST-1 assay was used to quantify cell proliferation Fibracol

PromogranVergenix

assay was used to quantify cell proliferation.

10

CollPlant's Business ModelThree Growth EnginesThree Growth Engines

ProductsProductsCollagen-based products ( )for soft and hard tissue repair;• Orthopedic & wound healing markets• Strategic collaborationsStrategic collaborations

CollaborationsSupply agreements with top tier

Raw MaterialSupply agreements with top-tier companies;• Supply collagen-based components

to end products

Raw material ( )For research applications;• Tissue culture & tissue eng. research

11

12

CollPlant’s RoadmapFocus on Major Unmet Medical Need

Composite Membranestructures

Biodegradable Implantfor repair of rotator cuff tears

Applications:Hernia meshes

cGMP Capability

Scalability &3rd party mfg.

High Strength Matrices*Composed of polymeric core & collagen shell

• Hernia meshes• Heart valve leaflets

Moldable Putty

W d D i

Flowable WoundMatrix Vergenix-B

Biodegradable Implantfor repair of ACL

Wound DressingMatrix

Matrix

Vergenix-WD

Microspheres for sustain release of BMP to augment

Vergenix-FG

Vergenix B

New biomaterials with unique physical properties

Applications:• Bone void filler • Osseous defectsApplications:

• Tunneled wounds• Surgical wounds• Ulcers• Draining wounds

Applications:• Surgical wounds• Ulcers

release of BMP to augment bone and soft tissue repair

Notes*:1 Thin strong matrices for minimally invasive surgery

Resilin Video

NP

2010 2011 2012

gUlcers• Draining wounds

1.Thin strong matrices for minimally invasive surgery2.Can be produced in different geometries

13

Forward Looking Statement Notice: The Company's estimations regarding the above mentioned Road Mapand Pipeline for the year 2010-2012 depend, among other things, on getting sufficient funds for R&Dprocedures, Company's compliance with Regulators' requests for regulatory approvals, and successfulcollaboration with strategic partners.

Advanced Suturable Sponge

Ke Attrib tesKey Attributes:• Tear resistance (wet or dry)

E tti• Easy wetting

• Easy to unfold

S t bl• Suturable

• Optional: contain microspheres for controlled release of growth factors.g

14

Vergenix™ Wound Gel Jump-Starts Wound Healing in a Rat ModelWound Healing in a Rat Model

• VergenixTM wound gel is a superior collagen formulation, designed to g g p g gjump-start wound healing

• VergenixTM wound gel provides a ready made scaffold, that degrades g g p y gin the wound within 7 days.

Each bar represents one animal

Wound with gel Secondary dressing

15

p

Bone Void Filler

Malleable cohesive Bone Void Filler administered by hand or syringeMalleable, cohesive Bone Void Filler, administered by hand or syringe

16

Growth Factors Controlled Release Using Gelatin MicrospheresUsing Gelatin Microspheres

• Microspheres fabrication methods adapted to CollPlant’s gelatin.

• Microspheres may be integrated into Vergenix Putty, Paste (bone void fillers) flowable gel and into advanced suturable spongesvoid fillers), flowable gel and into advanced suturable sponges.

• Microspheres are tested for BMP2 and BMP12 release profile.

17

Resilin/Collagen Elastic Spheres for Nucleus Pulposus Replacement/AugmentationPulposus Replacement/Augmentation

The Commercial Opportunity forMusculoskeletal Tissue RepairMusculoskeletal Tissue Repair

Rotator cuff (325,000 US)ACL (250,000 US) Hand/Wrist tendons (115,000 US)

Insi

ght

e: M

edte

chS

ourc

e

Spinal fusion (200,000 US)Putty for  BMP delivery

Nucleus Pulposus (300,000 US)  Meniscectomy 875,000 USRepair 64,000US

19Assuming ASP of $3K the annual US market potential for the above indications is $3.75B.

Potential Strategic Partnersfor Joint Development & Commercializationfor Joint Development & Commercialization

20

"Forward Looking Statement Notice: The Company's estimations regarding the above mentioned PotentialStrategic Partners depend, among other things, on Market Demand and medical needs, newmedical and/or scientific developments and mutual understandings between the Company and suchstrategic Partners, which are not entirely in Company's control and might not come to pass eventually."

Procollagen, a Bioactive Molecule for Regenerative MedicineRegenerative Medicine

Collagen deposition

ProcollagenM

Angiogenesis

Collagen deposition Telo-peptide cross-linking

Peptide chemotaxisAugmentation

of ECM production

Modulate cell functionPro α1

Pro α2

Cell chemotaxis

Negative feedback on excessive collagen synthesis

production

g yPrevent scar formation and fibrosis

A l t d d h li & ti iAccelerated wound healing & tissue repair

8% SDS-PAGE

21

Raw Material DistributionCollage rh™Collage rh™

• Signed Distribution agreement with FUNAKOSHI Co.,Ltd (J ) l di di t ib t f th R&D k tLtd. (Japan), a leading distributor for the R&D market.

• Exploring additional distribution channels.p g

22

Board and Management

Senior Management: Board of Directors:• Yehiel Tal, CEO

Regentis Biomaterials, ProChon Biotech, Kulicke & Soffa.• Oded Shoseyov Prof CSO Co-Founder

• Efi Cohen-Arazi, ChairmanIntec Pharma, Amgen, Immunex, Serono.

• Ran NussbaumOded Shoseyov, Prof., CSO, Co-FounderHebrew University of Jerusalem.

• Alon Bloomenfeld, CFOBiomedix, Runcom technologies, BrightCom Technologies.

Ran NussbaumPontifax VC.

• Elad NaggarBiomedix Incubator, Endogun, MindGuard.

• Noa Lapidot, PhD, EVP Operations & Dev.Intec Pharma, Sol-Gel Technologies, Electric Fuel, Teva.

H it A it i PhD VP R&D

• Oded Shoseyov, Prof.Co-Founder.

• Alon Dumanis, PhD• Hagit Amitai, PhD, VP R&DCompugen, QBI, Quantomix , InterPharm-Serono.

,Docor International Management.

• Liron EderyR.E.G.L.

• Eyal BigonTFG.

23

Financials

• Merger with Portfolio Green on May 20, 2010• Total raising by merger ~14.5M NIS • Total cash on June 30, 2010 at bank ~17.6M NIS

A d OCS t f 3 9M NIS f FY2010 i d • Approved OCS grant of 3.9M NIS for FY2010 received on July amount of 1,36M NIS from the approved grant

• Average monthly burn rate ~ 1.6M NIS• Expected initial income during 2010

24Forward Looking Statement Notice: The Company's estimations regarding the above mentioned initial incomeduring 2010 depend, among other things, on signing co-development agreements with other companies.

Stock informationStock information

• Total issued shares -108.5M ( including 2.7M dormant shares)• Total shares in fully diluted basis 160M (excluding dormant shares)• Total shares in fully diluted basis – 160M (excluding dormant shares)• Options/Warrants information:

other informationEx. PriceQuantity

Options as part of the merger from 2008 until 2012( Excluding 2.76M dorment options)2.02*13,615,275Options as part of the merger from 2010 until 20141.28720,700,000ESOP13,579,753Warrants in Collplant Ltd until 20122.09**7,620,898Total Options55,515,926

The Ex. Will be updated to 2.18 on June 2011 *21289 Warranst in Collplant Ltd with Ex. Price of $196.6 per option**

25

Use of cash proceedsp

• Development of pipeline productsBD activities towards join development and sales• BD activities towards join development and sales

• Regulation processg p• Expanding company manufacturing facility• Producing row material for sales in R&D market

26

The CollPlant Opportunity

• Unique, protected technology• Clear, Unmet Medical Need• Large growing multi-billion $ market• Large, growing multi-billion $ market• Large scale production capability of recombinant human collagencollagen

• Platform for biomaterials, regenerative medicine and drug deliverydelivery

• Rich and attractive pipeline• Experienced & knowledgeable leadership Team

27

Forward Looking Statement Notice: The Company's estimations regarding the above mentionedPipeline depend, among other things, on getting sufficient funds for R&D procedures, regulators'compliance with Company's requests for regulatory approvals, and successful collaboration withstrategic partners.

Thank You

28